HIV & AIDS

CD4 testing

CD4 count enables clinicians to determine when to initiate antiretroviral (ARV) treatment. BD CD4 testing reagents help evaluate the effectiveness of and adherence to ARV therapy. CD4 cell counts will continue to play an important part in initial decisions around ART initiation and clinical management of opportunistic infections, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted. Since 2002, BD has been in partnership with the Clinton Health Access Initiative (CHAI) to expand access to CD4 testing in Africa, Asia, Latin America and Eastern Europe and to provide deeply discounted pricing, of up to nearly 75%. In 2014, BD launched the BD FACSPresto™ CD4 instrument, a near-patient, complete CD4 testing solution, designed to improve patient access to CD4 testing. BD and CHAI are continuing their partnership on a CD4 access solution to ensure appropriate instruments are placed at various levels of the healthcare system, enabling governments to efficiently manage changing dynamics in the HIV staging and monitoring market.

Health systems strengthening

Our BD-PEPFAR Labs For Life and Safer Blood Collection collaborations have helped strengthen the systems and skills necessary to improve diagnostic testing capabilities for HIV & AIDS.

Read more about our Collaborations